Watch CCCC. Know when insiders buy.
One email the day a filing lands. Free.
CCCC
C4 Therapeutics, Inc.
3.44
−0.11 −3.10%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
23
FLAG · shorts 23
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $423.2MP/E —DIV YIELD —FCF YIELD -20.18%REV TTM $35M +2.3%NET INCOME −$101.4MNET CASH $68.3M52W 1.71 – 4.67SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $6.6M | +2.8% | — | −$26.4M | −$23.6M | — | -0.18 | −$1.6M | $37K | −$1.6M | Aug 11 |
| Q1 2026 · Mar 31 | $6.2M | −15.0% | — | −$27.8M | −$25.1M | — | -0.20 | −$29.9M | $64K | −$30M | Aug 11 |
| Q4 2025 · Dec 31derived | $11M | +112.8% | — | −$23.1M | −$20.5M | — | -0.09 | −$22.1M | $11K | −$22.2M | Feb 26 |
| Q3 2025 · Sep 30 | $11.2M | −26.9% | — | −$34.4M | −$32.2M | — | -0.44 | −$31.2M | $411K | −$31.6M | Nov 6 |
| Q2 2025 · Jun 30 | $6.5M | −46.2% | — | −$28.5M | −$26M | — | -0.37 | −$12.1M | $185K | −$12.2M | Aug 11 |
| Q1 2025 · Mar 31 | $7.2M | +138.2% | — | −$29.2M | −$26.3M | — | -0.37 | −$33.3M | $0 | −$33.3M | Aug 11 |
| Q4 2024 · Dec 31derived | $5.2M | +58.8% | — | −$37.7M | −$34.6M | — | -0.49 | −$17.9M | −$4K | −$17.9M | Feb 26 |
| Q3 2024 · Sep 30 | $15.4M | +38.7% | — | −$28.2M | −$24.7M | — | -0.35 | −$24.1M | −$13K | −$24.1M | Nov 6 |
| Q2 2024 · Jun 30 | $12M | — | — | −$21.4M | −$17.7M | — | -0.26 | −$5M | $197K | −$5.2M | Nov 6 |
| Q1 2024 · Mar 31 | $3M | — | — | −$32.2M | −$28.4M | — | -0.41 | −$18.1M | $0 | −$18.1M | Nov 6 |
| Q4 2023 · Dec 31derived | $3.3M | — | — | −$37.4M | −$34.8M | — | -0.68 | −$24M | $157K | −$24.2M | Feb 27 |
| Q3 2023 · Sep 30 | $11.1M | — | — | −$27.8M | −$27M | — | -0.55 | −$30.7M | $600K | −$31.3M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $35.9M | — | −$115.2M | −$105M | -292.1% | -1.27 | −$98.7M | $607K | −$99.3M | $193K | — |
| FY2024 · to Dec 31 | $35.6M | — | −$119.6M | −$105.3M | -296.0% | -1.52 | −$65.2M | $180K | −$65.3M | $194K | — |
| FY2023 · to Dec 31 | $20.8M | — | −$139M | −$132.5M | -638.3% | -2.67 | −$106.8M | $1.7M | −$108.5M | $110K | — |
| FY2022 · to Dec 31 | $31.1M | — | −$129.5M | −$128.2M | -412.2% | -2.62 | −$105.9M | $5.5M | −$111.4M | $0 | — |
| FY2021 · to Dec 31 | $45.8M | — | −$82.1M | −$83.9M | -183.2% | -1.82 | −$87M | $1.3M | −$88.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$60.4M | −$66.3M | — | -5.83 | −$67.2M | $650K | −$67.9M | $194K | — |
Every number comes from C4 Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.